Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
49 Results for "
T. brucei
" in MedChemExpress (MCE) Product Catalog:
Products (49)
49 Results for "T. brucei" in MCE Product Catalog:
4
Fexinidazole (HOE 239) is an orally active, potent nitroimidazole antitrypanosomal agent. Fexinidazole shows trypanocidal activity against T. brucei subspecies and strains with IC50s of 0.7-3.3 μM (0.2-0.9 μg/ml). Fexinidazol has the potential for human sleeping sickness (HAT) caused by infection with T. brucei .
3
Acoziborole (SCYX-7158) is an effective, safe and orally active antiprotozoal agent for the research of human african trypanosomiasis (HAT). In the T. b. brucei S427 strain, the MIC value for SCYX-7158 is 0.6 μg/mL .
1
1 Cited Publications
Cat. No.: HY-N2230
CAS No.: 36417-86-4
Category:
Plant Simple Phenylpropanols Phenols Polyphenols Ophiopogon japonicus (L. f.) Ker Gawl. Extract Phenylpropanoids Liliaceae Extract Asparagaceae Extract
Target:
1
1 Cited Publications
ML251, a potent nanomolar T. brucei and T. cruzi phosphofructokinase (PFK) inhibitor, inhibits T. brucei PFK (IC50=0.37 μM) and T. cruzi PFK (IC50=0.13 μM). ML251 can be used for the research of parasite .
Cat. No.: HY-128268
CAS No.: 735303-62-5
PFK-IN-1 (compound 1) is a phosphofructokinase (PFK) inhibitor, with IC50 values of 0.41 and 0.23 μM against T.brucei and T.cruzi PFK, respectively, and an ED50 of 15.18 μg/mL for T.brucei. The half-lives of PFK-IN-1 in rat and mouse liver microsomes are 9.7 and 408 minutes, respectively .
Cat. No.: HY-W052512
CAS No.: 75144-12-6
Antitrypanosomal agent 1 is a potent and selective trypanothione reductase (TR) inhibitor with an IC50 of 3.3 μM. Antitrypanosomal agent 1 inhibits glutathione reductase (GR) (IC50=64.8 μM) and T. brucei (EC50=1 μM). Antitrypanosomal agent 1 has anti-trypanosomal activity .
Cat. No.: HY-169728
CAS No.: 378197-09-2
Target:
Research Areas:
SID 24785302 is a hexokinase inhibitor with antiparasitic activity. SID 24785302 exhibits activity against T. brucei and Leishmania. SID 24785302 can be used for the research of mitochondrial DNA disorders and parasitic infection .
Cat. No.: HY-W043676
CAS No.: 1210-34-0
Target:
Research Areas:
Dibenzosuberol (Compound 2) is a key intermediate in the synthesis of compounds associated with inhibiting Trypanosoma thiol reductase (TryR). Dibenzosuberol also shows inhibition of T. brucei with an EC50 value of 51.3 μM. Dibenzosuberol is also an impurity of Amitriptyline (HY-B0527) .
Cat. No.: HY-N7634
CAS No.: 24449-39-6
Target:
Cat. No.: HY-155732
CAS No.: 3032452-65-3
NPD-2975 (compound 30) is an orally active antitrypanosomal agent, against Human African Trypanosomiasis (HAT). NPD-2975 has low toxicity potential against human MRC-5 lung fibroblasts, and acute mouse model of T. b. brucei infection. NPD-2975 shows acceptable metabolic stability, inhibits T. b. brucei with IC500 of 70 nM in vitro. NPD-2975 also inhibits CYP enzymes resulted in IC50 values of 0.16 and 0.42 μM against CYP1A2 and CYP2C19, respectively .
Cat. No.: HY-Q40175
CAS No.: 438474-67-0
Antitrypanosomal agent 9 (compound 1) is a potent antitrypanosomal agent. Antitrypanosomal agent 9 shows inhibitory activity against T. b. brucei, with an IC50 of 1.15 μM. Antitrypanosomal agent 9 can be used for human African trypanosomiasis (HAT) research .
Cat. No.: HY-155531
CAS No.: 3052256-03-5
Target:
Research Areas:
PEX5-PEX14 PPI-IN-2 (compound 12) is a PEX14-PEX5 protein-protein interaction (PPI) inhibitor. PEX5-PEX14 PPI-IN-2 inhibits PEX14-PEX5 PPI with EC50 values of 5 and 17 µM in T. b. brucei and HepG2 cells, respectively. PEX5-PEX14 PPI-IN-2 can be used in the research of diseases related to trypanosome infection .
Cat. No.: HY-W009689
CAS No.: 17557-67-4
TbPTR1 inhibitor 2 (Compound 3a) is a PTR1 enzyme inhibitor, with IC50s of 34.2 and 32.9 μM for TbPTR1 and LmPTR1. TbPTR1 inhibitor 2 has anti-parasitic activity against T. brucei (IC50: 34.2 μM) .
Cat. No.: HY-155530
CAS No.: 3052256-26-2
PEX5-PEX14 PPI-IN-1 (Compound 8) is a PEX14-PEX5 PPI inhibitor. PEX5-PEX14 PPI-IN-1 disrupts the PEX5-TbPEX14 PPI with a Ki of 53 μM. PEX5-PEX14 PPI-IN-1 inhibits the bloodstream form of T. b. brucei (EC50: 5 μM) .
Cat. No.: HY-170363
CAS No.: 3063720-23-7
Target:
Research Areas:
Proteasome-IN-6 (Compound J-80) inhibits the β5 catalytic subunit of the Trypanosoma brucei 20S proteasome, inibits T. b. brucei, T. b. gambiense and T. b. rhodesiense with EC50s of 157 nM, 220 nM and 156 nM, respectively. Proteasome-IN-6 exhibits antitrypanosomal activity in mouse model .
Cat. No.: HY-146049
CAS No.: 2456427-48-6
Antitrypanosomal agent 4 (compound 19) is a potent and blood-brain barrier permeable antitrypanosomal agent. Antitrypanosomal agent 4 has good activity against Trypanosoma cruzi (T. cruzi) and Trypanosoma brucei brucei (T. b. brucei) with IC50s of 1.2 μM and 70 nM, respectively . Antitrypanosomal agent 4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-13801R
CAS No.: 59729-37-2
Synonyms: HOE 239 (Standard)
Target:
Research Areas:
Fexinidazole (Standard) is the analytical standard of Fexinidazole. This product is intended for research and analytical applications. Fexinidazole (HOE 239) is an orally active, potent nitroimidazole antitrypanosomal agent. Fexinidazole shows trypanocidal activity against T. brucei subspecies and strains with IC50s of 0.7-3.3 μM (0.2-0.9 μg/ml). Fexinidazol has the potential for human sleeping sickness (HAT) caused by infection with T. brucei .
Cat. No.: HY-116045
CAS No.: 1622300-88-2
PDEB1-IN-1 (Compound 12b) is the derivative of Cilomilast (HY-10790), and serves as an inhibitor for TryPanosoma Brucei PDEB1 (TbrPDEB1) with an IC50 of 0.95 μM. PDEB1-IN-1 inhibits the proliferation of T. Brucei with an EC50 of 26 μM .
Cat. No.: HY-111906
CAS No.: 1222509-12-7
Target:
Research Areas:
SCYX-6759 is an orally active, blood-brain barrier permeable anti-T. brucei agent. SCYX-6759 inhibits cytochrome P450 (IC50s: 30.3, 30.6, 47.4 μM for 2D6, 2C9, 2C19, respectively.) SCYX-6759 exhibits potent activity against T. b. brucei 427, T. b. rhodesiense STIB900, and T. b. gambiense STIB930, with IC50s of 0.07, 0.038 and 0.030 μg/mL, respectively .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
